BioNxt Solutions Inc.
BNXT
CNSX
| Weiss Ratings | BNXT - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | BNXT - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BNXT - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.57 | |||
| Price History | BNXT - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 2.00% | |||
| 30-Day Total Return | 27.50% | |||
| 60-Day Total Return | 70.00% | |||
| 90-Day Total Return | 100.00% | |||
| Year to Date Total Return | 21.43% | |||
| 1-Year Total Return | -15.00% | |||
| 2-Year Total Return | -29.17% | |||
| 3-Year Total Return | -46.88% | |||
| 5-Year Total Return | -68.13% | |||
| 52-Week High % Change | -18.84% | |||
| 52-Week Low % Change | 229.41% | |||
| Price | BNXT - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.69 | |||
| 52-Week Low Price | $0.17 | |||
| 52-Week Low Price (Date) | Jun 21, 2024 | |||
| 52-Week High Price (Date) | Mar 03, 2025 | |||
| Valuation | BNXT - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 44.22M | |||
| Enterprise Value | 48.06M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.04 | |||
| Earnings Per Share Growth | -55.92% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 2,800.00 | |||
| Price/Book (Q) | -11.57 | |||
| Enterprise Value/Revenue (TTM) | 1,555.43 | |||
| Price | $0.51 | |||
| Enterprise Value/EBITDA (TTM) | -12.45 | |||
| Enterprise Value/EBIT | -12.21 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BNXT - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 113.02M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BNXT - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 780 818 6422 | |||
| Address | 1820 Fir Street Vancouver, BC V6J 3B1 | |||
| Website | www.bionxt.com | |||
| Country | Canada | |||
| Year Founded | 2017 | |||
| Profitability | BNXT - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -12,735.92% | |||
| Profit Margin | -15,422.65% | |||
| Management Effectiveness | BNXT - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -254.65% | |||
| Return on Equity | -- | |||
| Income Statement | BNXT - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 30.90K | |||
| Total Revenue (TTM) | 30.90K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | 30.90K | |||
| EBITDA (TTM) | -3.86M | |||
| EBIT (TTM) | -3.94M | |||
| Net Income (TTM) | -4.77M | |||
| Net Income Avl. to Common (TTM) | -4.77M | |||
| Total Revenue Growth (Q YOY) | 190.70% | |||
| Earnings Growth (Q YOY) | -2.67% | |||
| EPS Diluted (TTM) | -0.04 | |||
| EPS Diluted Growth (Q YOY) | 10.38% | |||
| Balance Sheet | BNXT - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 59.30K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 210.90K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -5.47M | |||
| Current Ratio (Q) | 0.035 | |||
| Book Value Per Share (Q) | -$0.05 | |||
| Total Assets (Q) | 529.70K | |||
| Total Current Liabilities (Q) | 6.00M | |||
| Total Debt (Q) | 4.16M | |||
| Total Liabilities (Q) | 6.00M | |||
| Total Common Equity (Q) | -5.47M | |||
| Cash Flow | BNXT - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 201.30K | |||
| Cash from Financing (TTM) | 1.80M | |||
| Net Change in Cash (TTM) | -384.30K | |||
| Levered Free Cash Flow (TTM) | -1.31M | |||
| Cash from Operations (TTM) | -2.39M | |||
